Free radicals and antioxidants in cardiovascular disease

British Journal of Clinical Pharmacology

Volumn 44, Issue 4, 1997, Pages 307-317

  Maxwell, Simon R J ^a   Lip, Gregory Y H ^b  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Antioxidants; Coronary artery disease; Free radicals; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; FREE RADICAL; HYDROXYL RADICAL; LIPOPROTEIN; SCAVENGER; SUPEROXIDE;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIETARY INTAKE; HUMAN; LIPID OXIDATION; LIPID PEROXIDATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0030881329     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00594.x     Document Type: Review

References (69)

1. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad Res Commun 1989; 6: 67-75.
2. Steinbrecher UP, Lougheed M, Kwan WC, Dirks M. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J Biol Chem 1989; 264: 15216-15223.
3. Halliwell B. How to characterize a biological antioxidant. Free Rad Res Commun 1990; 9: 1-32.
4. Halliwell B, Gutteridge JMC. The antioxidants of human extracellular fluids. Arch Biochem Biophys 1990; 280: 1-8.
5. Stocker R, Frei B. Endogenous antioxidant defences in human blood plasma. In Oxidative stress: oxidants and antioxidants. ed Sies H. London: Academic Press, 1991; 213-242.
6. Packer JE, Slater TF, Wilson RL. Direct observation of a free radical interaction between vitamin E and vitamin C. Nature 1979; 278: 737.
7. Steinberg D, Parsatharathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
8. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Ann Rev Biochem 1977; 46: 897-930.
9. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Ann Rev Biochem 1983; 52: 223-261.
10. Morel DW, DiCorleto PE, Chisholm GM. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 1984; 4: 357-364.
11. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: Recognition by the receptor for acetylated low density lipoproteins. Proc Natl Acad Sci USA 1981; 78: 6499-6503.
12. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical Biology and Medicine 1992; 13: 341-390.
13. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxid-ation and hydroxyl radical generation by the contents of human atherosclerotic lesions. Biochem J 1992; 286: 901-905.
14. Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Ahlström C, Fager G, Bondjers G. Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arteriosclerosis Thrombosis 1992; 12: 569-583.
15. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/ macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84: 2995-2998.
16. Navab M, Imes S, Hama S, et al. Monocyte transmigration induced by modifications of LDL in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein I synthesis and is abolished by HDL. J Clin Invest 1991; 88: 2039-2046.
17. Hessler JR, Robertson AL Jr., Chisolm GM. LDL cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cell culture. Atherosclerosis 1979; 32: 213.
18. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelial-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344: 160-162.
19. Ylä-Herttuala S, Palinski W, Rosenfield ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086-1095.
20. Palinski W, Rosenfeld ME, Ylä-Herttuala S, et al. Low-density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86: 1372-1376.
21. Salonen JT, Ylä-Herttuala S, Yamomoto R, et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-887.
22. Jessup W, Rankin SM, De Whalley CV, Hoult JRS, Scott J, Leake DS. Alpha-tocopherol consumption during low-density-lipoprotein oxidation. Biochem J 1990; 265: 399-405.
23. Stocker R, Bowry VW, Frei B. Ubiquinol-10 protects human low-density lipo-protein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci USA 1991; 88: 1646-1650.
24. Esterbauer H, Puhl H, Dieber-Rotheneder M, Waeg G, Rabl H. Effect of antioxidants on oxidative modification of LDL. Ann Med 1991; 23: 573-581.
25. Reaven PD, Khouw A, Beltz WF, Parthasarathy S, Witztum JL. Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene. Arteriosclerosis Thrombosis 1993; 13: 590-600.
26. Reaven PD, Parthasarathy S, Grasse BJ, Miller E, Steinberg D, Witztum JL. Effects of oleate-rich and linoleate rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolaemic subjects. J Clin Invest 1993; 91: 667-668.
27. Parthasarathy S, Khoo JC, Miller E, Barnett J, Witztum JL, Steinberg D. Low density lipoprotein rich in oleic acids is protected against oxidative modification: Implications for dietary prevention of atherosclerosis. Proc Natl Acad Sci USA 1990; 87: 3894-3898.
28. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992; 93: 189-199.
29. Lynch SM, Frei B. Antioxidants as antiatherogens: animal studies. In Natural antioxidants in human health and disease Academic Press Inc 1994; 353-358.
30. Wilson RB, Middleton CC, Sun GY. Vitamin E, antioxidants and lipid peroxidation in experimental atherosclerosis of rabbits. J Nutrition 1978; 108: 1858-1867.
31. Wojcicki J, Rozewicka L, Barcew-Wiszniewska B, et al. Effect of selenium and vitamin E on the development of experimental atherosclerosis in rabbits. Atherosclerosis 1991; 87: 9-16.
32. Williams RJ, Motteram JM, Sharp CH, Gallagher PJ. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis 1992; 94: 153-159.
33. Keaney JF Jr., Gaziano JM, Xu A, et al. Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994; 93: 844-851.
34. Ginter E. Marginal vitamin C deficiency, lipid metabolism and atherogenesis. Adv Lipid Res 1978; 16: 167-220.
35. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect. Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks slowing the progression of atherosclerosis in the WHHL rabbit. Proc Natl Acad Sci USA 1987; 84: 7725-7729.
36. Regnström J, Walldius G, Carlson A, Nilsson J. Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolaemic patients to become oxidatively modified in vitro. Atherosclerosis 1990; 82: 43-51.
37. Björkhem I, Henriksson-Freyschuss A, Breuer O, Dietztalusy V, Berglund L, Henriksson P. The anti-oxidant butylated hydroxytoluene protects against athero-sclerosis. Arteriosclerosis Thrombosis 1991; 11: 15-22.
38. Armstrong BK, Mann JL, Adelstein AM, Eskin F. Commodity consumption and ischaemic heart disease mortality with special reference to dietary practices. J Chronic Dis 1975; 36: 673-677.
39. Verlangieri AJ, Kapeghian JC, El-Dean S, Bush M. Fruit and vegetable consumption and cardiovascular disease mortality. Med Hypotheses 1985; 16: 7-15.
40. Ginter E. Decline of coronary mortality in the United States and vitamin C. Am J Clin Nutr 1979; 32: 511-512.
41. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischaemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991; 53 (Suppl.1): 326S-334S.
42. Riemersma RA, Oliver M, Elton MA, et al. Plasma antioxidants and coronary heart disease: Vitamins C and E and selenium. Eur J Clin Nutr 1990; 44: 143-150.
43. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA. Rosner B, Willett C. Vitamin E consumption and the risk of coronary artery disease in women. N Engl J Med 1993; 328: 1444-1449.
44. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and risk of coronary artery disease in men. N Engl J Med 1993; 328: 1450-1456.
45. Enstrom JE, KaniM LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992; 3: 194-202.
46. Lapidus L, Anderson H, Bengtson C, Bosceus I. Dietary habits in relation to cardiovascular disease and death in women: a 12 year follow-up of participants in the study of women in Gothenberg, Sweden. Am J Clin Nutr 1986; 44: 444-448.
47. Gaziano JM, Hennekens CH. The role of beta-carotene in the prevention of cardiovascular disease. Ann NY Acad Sci 1993; 691: 148-155.
48. Hodis HN, Mack WJ, LaBree L, Cashin-Hemphill L, Sevanian A, Johnson R, Azen SP. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995; 273: 1849-1854.
49. Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein in by phenolic substances in red wine. Lancet 1993; 341: 454-457.
50. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly study. Lancet 1993; 342: 1007-1011.
51. Gey KF, Stahelin HB, Eicholzer M. Poor plasma status of carotene and vitamin C is associated with higher mortality from ischaemic heart disease and stroke: Basel prospective study. Clin Invest 1993; 71: 3-6.
52. Morris DL, Kritchevsky SB, Davis CE. Serum carotenoids and coronary heart disease in the Lipid Research Clinics Primary Prevention Trial. Circulation 1993; 87: 2.
53. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and and cardiovascular disease: a critical review of epidemiologic and clinical trial data. Ann Intern Med 1995; 123: 860-872.
54. Kardinaal AFM, Kok FJ, Ringstad J, et al. Antioxidants in adipose tissue and risk of myocardial infarction: the EURAMIC study. Lancet 1993; 342: 1379-1384.
55. Riemersma RA, Wood DA, MacIntyre CC, Elton R, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A, C, E and carotene. Lancet 1991; 337: 1-5.
56. Ramirez J, Flowers NC. Leukocyte ascorbic acid and its relationship to coronary heart disease in man. Am J Clin Nutr 1980; 33: 2079-2087.
57. Kok FJ, de Bruijn AM, Vermeeren R, et al. Serum selenium, vitamin antioxidants and cardiovascular mortality : A 9 year follow-up study in the Netherlands. Am J Clin Nutr 1987; 45: 462-468.
58. Salonen JT, Salonen R, Penttila I, et al. Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and risk of death from coronary artery disease. Am J Cardiol 1985; 56: 226-231.
59. Street DA, Comstock GW, Salkeld RM, Shuep W, Klag M. A population based case-control study of serum antioxidants and myocardial infarction. Am J Epidemiology 1991; 134: 719-720.
60. Gaziano JM, Manson JE, Ridker PM, Buring JE, Hennekens CH. Beta-carotene therapy for chronic stable angina pectoris. Circulation 1990; 82: Suppl.III 202 (Abstract).
61. The alpha-Tocopherol, beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-1035.
62. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-786.
63. Hennekens CH, Eberlain K. A randomised trial of aspirin and beta-carotene among US physicians. Preventative Med 1985; 14: 165-168.
64. Buring JE, Hennekens CH. Randomised trials of primary prevention of cardiovascular disease in women. An investigators view. Ann Epidemiol 1994; 4: 111-114.
65. Stephens NG, Parsons A, Cheeseman K, Kelly F, Schofield PM, Mitchinson MJ, Brown MJ. Anticoagulant effects of vitamin E treatment in patients with coronary disease. Eur Heart J 1996; 17(Abstract Suppl): 536.
66. Steiner M. Influence of Vitamin E on platelet function in humans. J Am Coll Nutr 1991; 10: 466-473.
67. Wu HP, Tai TY, Chuang LM, Lin BJ, Wang JD, Teng CM. Effect of tocopherol platelet aggregation in non-insulin-dependent diabetes mellitus: ex vivo and in vitro studies. J Formosan Med Assoc 1992; 91: 270-275.
68. Dowd P, Zheng ZB. On the mechanism of the anticlotting action of vitamin E quinone. Prof Natl Acad Sci USA 1995; 92: 8171-8175.
69. Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, Luscher TF. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and procine endothelium. Circ Res 1992; 70: 1191-1197.